Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242121640> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4242121640 endingPage "272" @default.
- W4242121640 startingPage "266" @default.
- W4242121640 abstract "Objective: Desloratadine is a biologically active metabolite of loratadine which is indicated for the treatment of allergic rhinitis. Bosentan is a dual endothelin receptor antagonist used to treatment of pulmonary artery hypertension (PAH). In this study, we aimed to determine the role of endothelins in allergic rhinitis (AR) and the effects of endothelin receptor antagonists in AR rat models through comparison with desloratadine. Methods: In total, 20 adult Sprague-Dawley rats were used in this study. An ovalbumin-induced allergic rhinitis model was formed in three study groups except for the control group. Bosentan (100 mg/kg/day) was given to the bosentan-treated group for 7 days and desloratadine (10 mg/kg/day) was administered to the antihistaminic-treated group for 7 days. Nasal symptom scorings and histopathological examinations of the nasal tissues were carried out. Serum IgE levels and ET-1 and TNF-alpha mRNA expression levels were analysed. Between group comparisons for nasal symptoms, histopathological analysis, and molecular analyses were performed with a one-way ANOVA and Duncans multiple comparison tests. Significance was accepted at p smaller than 0.05. Results: Bosentan inhibited nasal symptom more significantly than desloratadine. The IgE level, ET-1 and TNF-alpha mRNA expression levels statistically increased in the allergic rhinitis group when compared to other groups. Conversely, the bosentan-treatment group showed a significant recovery from the same parameters. The deterioration in histopathological parameters reached the highest levels in the allergic rhinitis group. The histopathological findings were close to those of the control group in the bosentan and antihistaminic-treated group. Conclusions: ET-1 is one of the mediators that impact AR development and ET-1 antagonists can be useful for symptom control and for decreasing allergic inflammation in AR patients." @default.
- W4242121640 created "2022-05-12" @default.
- W4242121640 creator A5001841181 @default.
- W4242121640 creator A5003281514 @default.
- W4242121640 creator A5016360122 @default.
- W4242121640 creator A5032246094 @default.
- W4242121640 creator A5061477385 @default.
- W4242121640 creator A5089887457 @default.
- W4242121640 date "2016-09-01" @default.
- W4242121640 modified "2023-09-27" @default.
- W4242121640 title "The role of endothelin-1 and endothelin receptor antagonists in allergic rhinitis inflammation: ovalbumin-induced rat model" @default.
- W4242121640 doi "https://doi.org/10.4193/rhino15.059" @default.
- W4242121640 hasPublicationYear "2016" @default.
- W4242121640 type Work @default.
- W4242121640 citedByCount "2" @default.
- W4242121640 countsByYear W42421216402022 @default.
- W4242121640 crossrefType "journal-article" @default.
- W4242121640 hasAuthorship W4242121640A5001841181 @default.
- W4242121640 hasAuthorship W4242121640A5003281514 @default.
- W4242121640 hasAuthorship W4242121640A5016360122 @default.
- W4242121640 hasAuthorship W4242121640A5032246094 @default.
- W4242121640 hasAuthorship W4242121640A5061477385 @default.
- W4242121640 hasAuthorship W4242121640A5089887457 @default.
- W4242121640 hasBestOaLocation W42421216401 @default.
- W4242121640 hasConcept C126322002 @default.
- W4242121640 hasConcept C144980905 @default.
- W4242121640 hasConcept C149601957 @default.
- W4242121640 hasConcept C170493617 @default.
- W4242121640 hasConcept C203014093 @default.
- W4242121640 hasConcept C207480886 @default.
- W4242121640 hasConcept C2776345702 @default.
- W4242121640 hasConcept C2776946954 @default.
- W4242121640 hasConcept C2779675166 @default.
- W4242121640 hasConcept C2780734495 @default.
- W4242121640 hasConcept C2781025919 @default.
- W4242121640 hasConcept C2781109936 @default.
- W4242121640 hasConcept C71924100 @default.
- W4242121640 hasConcept C8891405 @default.
- W4242121640 hasConcept C90924648 @default.
- W4242121640 hasConcept C98274493 @default.
- W4242121640 hasConceptScore W4242121640C126322002 @default.
- W4242121640 hasConceptScore W4242121640C144980905 @default.
- W4242121640 hasConceptScore W4242121640C149601957 @default.
- W4242121640 hasConceptScore W4242121640C170493617 @default.
- W4242121640 hasConceptScore W4242121640C203014093 @default.
- W4242121640 hasConceptScore W4242121640C207480886 @default.
- W4242121640 hasConceptScore W4242121640C2776345702 @default.
- W4242121640 hasConceptScore W4242121640C2776946954 @default.
- W4242121640 hasConceptScore W4242121640C2779675166 @default.
- W4242121640 hasConceptScore W4242121640C2780734495 @default.
- W4242121640 hasConceptScore W4242121640C2781025919 @default.
- W4242121640 hasConceptScore W4242121640C2781109936 @default.
- W4242121640 hasConceptScore W4242121640C71924100 @default.
- W4242121640 hasConceptScore W4242121640C8891405 @default.
- W4242121640 hasConceptScore W4242121640C90924648 @default.
- W4242121640 hasConceptScore W4242121640C98274493 @default.
- W4242121640 hasIssue "3" @default.
- W4242121640 hasLocation W42421216401 @default.
- W4242121640 hasOpenAccess W4242121640 @default.
- W4242121640 hasPrimaryLocation W42421216401 @default.
- W4242121640 hasRelatedWork W2030804669 @default.
- W4242121640 hasRelatedWork W2093180041 @default.
- W4242121640 hasRelatedWork W2369362743 @default.
- W4242121640 hasRelatedWork W2372776271 @default.
- W4242121640 hasRelatedWork W2381977691 @default.
- W4242121640 hasRelatedWork W2387471016 @default.
- W4242121640 hasRelatedWork W2419088734 @default.
- W4242121640 hasRelatedWork W2898845055 @default.
- W4242121640 hasRelatedWork W4240313045 @default.
- W4242121640 hasRelatedWork W4242121640 @default.
- W4242121640 hasVolume "54" @default.
- W4242121640 isParatext "false" @default.
- W4242121640 isRetracted "false" @default.
- W4242121640 workType "article" @default.